Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

219
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
219
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

305
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroplasticity and neuroimmune interactions with type 2 inflammation in asthma.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Freeze-Drying in Sucrose Followed by Cryomilling Enables the Formulation of sa-mRNA-LNP Powders for Inhalation.

Pharmaceutics·2026
Same author

Leucine Protects Dry Powders for Inhalation Against Irreversible Moisture-Induced Aggregation.

Pharmaceutics·2025
Same author

An In Vitro-In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops.

Pharmaceutics·2025
Same author

Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.

Pharmaceutics·2025
Same author

Extracellular vesicles from bronchoalveolar lavage fluid provide insights into the inhaled corticosteroids treatment response in COPD.

Respiratory research·2025

Related Experiment Video

Updated: May 28, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K

Stabilized Extracellular Vesicle Formulations for Inhalable Dry Powder Development.

Eva M Jansen1, Luke van der Koog2,3, Robin A B Elferink2

  • 1Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, Groningen, 9713 AV, The Netherlands.

Small (Weinheim an Der Bergstrasse, Germany)
|February 13, 2025
PubMed
Summary

Inulin stabilizes extracellular vesicles (EVs) for chronic obstructive pulmonary disease (COPD) treatment, enabling storage at room temperature. This improves accessibility for inhalable EV therapies globally.

Keywords:
inulinlung fibroblastslyophilizationmannitolorganoidsprocess stabilitystorage stability

More Related Videos

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

785
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.0K

Related Experiment Videos

Last Updated: May 28, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

785
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.0K

Area of Science:

  • Biotechnology
  • Regenerative Medicine
  • Pulmonary Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) is a major global health challenge, particularly impacting low- and middle-income countries.
  • Extracellular vesicles (EVs) show promise for COPD treatment but require ultra-low temperature storage (-80°C), limiting accessibility.
  • Developing accessible EV-based therapies is crucial for global health equity.

Purpose of the Study:

  • To investigate alternative storage methods for extracellular vesicles (EVs) to enhance stability and accessibility.
  • To evaluate the efficacy of inulin and mannitol as stabilizers for EVs.
  • To develop a practical, inhalable EV formulation for COPD treatment.

Main Methods:

  • EVs from lung fibroblasts were subjected to freezing, freeze-drying, and spray-drying with inulin or mannitol.
  • Biophysical properties and functionality were assessed using lung organoid formation assays.
  • Stability was evaluated after storage at various temperatures and humidity levels.
  • Inhalable powder formulation and lung deposition were tested.

Main Results:

  • Inulin effectively stabilized EVs, preserving functionality after freezing at -20°C for 12 weeks.
  • Freeze-drying EVs with inulin maintained stability at 20°C and 43% relative humidity.
  • Spray-dried EVs with inulin and leucine formed a stable, inhalable powder with good lung deposition.
  • Mannitol led to EV aggregation and reduced bio-functionality.

Conclusions:

  • Inulin is a promising stabilizer for extracellular vesicles (EVs), enabling ambient temperature storage.
  • This approach eliminates the need for ultra-low temperature storage, significantly improving the accessibility of EV therapies.
  • Inulin-based inhalable EV powders offer a practical and effective new treatment strategy for COPD.